Johnson & Johnson Reports 45% Complete Response Rate Sustained Over One Year with TAR-200 in BCG-Unresponsive High-Risk NMIBC

Recently, Johnson & Johnson announced the durability data of its bladder cancer drug TAR-200. TAR-200 is a drug-device combination used to treat certain patients with bladder cancer. The released data shows that the drug has a high complete response rate and durability in treating bladder cancer.

TAR-200 is an innovative intravesical drug delivery system capable of continuously releasing the chemotherapy drug gemcitabine directly into the bladder. This drug-device combination is designed to provide a new treatment option for high-risk non-muscle-invasive bladder cancer (NMIBC) patients who are unresponsive to Bacillus Calmette-Guérin (BCG).

At the annual meeting of the American Urological Association held in Las Vegas, research results released on Saturday showed that patients who receivedNearly 45% of patients treated with TAR-200 achieved complete response (CR) status., and was maintained for at least 12 months. These data indicate that TAR-200 has significant efficacy and durability in the treatment of high-risk NMIBC.

The Phase IIb SunRISe-1 study of TAR-200 was published in January this year. The study showed that patients receivingIn patients treated with TAR-200 monotherapy, the complete response rate (CR) reached 83.5%, and at a median follow-up of 9 months, 82% of patients maintained a complete response.

Johnson & Johnson submitted a rolling application for TAR-200 to the U.S. Food and Drug Administration (FDA) in January 2025. The application is supported by the FDA's Real-Time Oncology Review (RTOR) program, which aims to expedite the approval process for certain oncology drugs or biologics.

TAR-200 has been granted Breakthrough Therapy Designation by the FDA, which will further expedite its development and review process.

Conclusion:

Bladder cancer is one of the top ten most common cancers globally, and patients with NMIBC have limited treatment options after initial BCG therapy fails. TAR-200 and its follow-up product TAR-210 are expected to play a significant role in the field of bladder cancer treatment, with Johnson & Johnson projecting that the peak sales of these two drugs could reach $5 billion.If approved, TAR-200 will become the first intravesical drug delivery system for this indication.

Disclaimer:

The content of the article is for reference only and does not constitute investment advice. Investors who take action based on this information bear their own risks. The article maintains a neutral stance on the statements and viewpoints expressed, and does not provide any explicit or implicit guarantees regarding the accuracy, reliability, or completeness of the content. Readers are advised to use it solely as a reference and assume full responsibility for their actions.